D R Burton Healthcare v. Trudell Medical & Monaghan: Federal Circuit Splits Decision on Respiratory Device Patent
D R Burton Healthcare, LLC asserted US9808588B1 — a patent covering oscillating positive respiratory pressure (OPEP) devices — against Trudell Medical International and Monaghan Medical Corp. The Federal Circuit issued a mixed ruling after 658 days, affirming some aspects of the lower decision, reversing others, and remanding for further proceedings.
Federal Circuit splits on OPEP device patent — case remanded for further review
D R Burton Healthcare, LLC filed appeal No. 23-1779 at the Court of Appeals for the Federal Circuit on 21 April 2023, challenging a lower-court decision involving US9808588B1. That patent protects oscillating positive respiratory pressure device technology, a therapeutic respiratory category with significant commercial competition. The defendants — Trudell Medical International and Monaghan Medical Corp. — are established players in the respiratory device market, represented by Crowell & Moring, LLP.
The Federal Circuit closed the case on 7 February 2025 with a nuanced outcome: the lower decision was affirmed in part, reversed in part, and the case remanded for further proceedings. The basis of termination also includes a partial dismissal of the appeal, suggesting that certain claims or procedural elements did not survive appellate review on their merits. The remand means the litigation is not fully resolved — specific issues return to the lower tribunal for reconsideration consistent with the Federal Circuit’s guidance.
The 658-day duration reflects the complexity typical of split Federal Circuit rulings, where multiple claim or validity issues are parsed independently. The partial reversal suggests the lower court erred on at least one material issue, while the affirmance indicates other findings were upheld. What specific claim constructions, validity determinations, or infringement findings were reversed versus affirmed remains subject to the full written opinion. The partial dismissal of the appeal adds further procedural nuance that the public docket record alone does not fully resolve.
Filing to Appeal Dismissed in Part in 658 days
658-day appeal duration — longer than the median Federal Circuit appeal cycle of ~500 days
Federal Circuit’s split ruling: what affirmed-in-part, reversed-in-part means for both parties
What ‘affirmed-in-part, reversed-in-part, remanded’ means
A split Federal Circuit ruling means the appellate panel found the lower court was correct on some issues but committed reversible error on others. Neither party achieved a complete win. The remand instruction sends specified issues back to the lower tribunal to be reconsidered in line with the Federal Circuit’s analysis. The partial dismissal of the appeal further signals that certain grounds were rejected at the appellate threshold without full merits review.
Partial reversal + remandD R Burton Healthcare: partial vindication, but case not closed
For D R Burton Healthcare, the partial affirmance preserves at least some of the lower-court findings in its favour, suggesting US9808588B1 retains enforceability on certain grounds. However, the partial reversal means one or more key determinations went against the patent holder at the appellate level. The remand reopens proceedings, extending litigation risk and cost. The patent’s ultimate enforceability against these defendants remains contingent on the remand outcome.
Enforceability contingent on remandTrudell Medical & Monaghan: reversal offers partial relief, not resolution
The partial reversal is a meaningful win for Trudell Medical International and Monaghan Medical Corp., indicating the Federal Circuit agreed with at least one of their appellate arguments. However, the affirmance of other aspects means full invalidity or non-infringement has not been established at this stage. With the case remanded, the defendants face continued exposure on the remaining live issues and must continue defending at the lower tribunal level.
Partial win; continued exposureOPEP device market: uncertainty persists while remand proceeds
The split ruling and remand create ongoing IP uncertainty in the oscillating positive respiratory pressure device segment. Competitors and product teams should note that US9808588B1 has survived appellate challenge in part and remains in active enforcement posture. The reversal on some grounds may narrow the patent’s effective scope or the damages base, but this will only become clear once the remand is resolved. FTO analysis against this patent remains advisable for any OPEP device developer or manufacturer.
OPEP sector risk remains elevatedFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | D R Burton Healthcare, LLC | Company | Healthcare IP licensor — holder of US9808588B1 covering oscillating positive respiratory pressure devicesSearch in Eureka ↗ |
| Defendant | Trudell Medical International | Individual | Trudell Medical International and Monaghan Medical Corp. — respiratory device manufacturersSearch in Eureka ↗ |
| Co-Defendant | Monaghan Medical, Corp. | Company | Search in Eureka ↗ |
| Plaintiff counsel | Albert P. Allan | Attorney | Counsel for D R Burton Healthcare, LLCSearch in Eureka ↗ |
| Plaintiff law firm | Allan Law Firm PLLC | Law Firm | Representing D R Burton Healthcare, LLCSearch in Eureka ↗ |
| Defendant counsel | Judy He | Attorney | Counsel for Trudell Medical InternationalSearch in Eureka ↗ |
| Defendant law firm | Crowell & Moring, LLP | Law Firm | Representing Trudell Medical InternationalSearch in Eureka ↗ |
| Presiding judge | Judge N/A | Judge | Court of Appeals for the Federal CircuitSearch in Eureka ↗ |
Official order — verbatim text
The Federal Circuit’s order — ‘AFFIRMED-IN-PART, REVERSED-IN-PART, AND REMANDED’ — is one of the most consequential mixed outcomes at the appellate level. It signals the panel applied a de novo standard to legal questions (such as claim construction) and found error on at least one ground, while upholding others under the applicable deferential standard. The accompanying partial dismissal of the appeal suggests certain issues were procedurally barred from merits review. The remand instruction obligates the lower tribunal to reconsider the reversed elements, keeping US9808588B1 in active litigation posture.
US9808588B1 — oscillating positive respiratory pressure device
US9808588B1 protects technology in the oscillating positive respiratory pressure (OPEP) device category — a class of therapeutic respiratory devices that generate oscillating back-pressure to assist airway clearance and lung function. Filed under application number US15/453767, the patent reflects innovation in a clinically established respiratory therapy segment used widely in the management of chronic obstructive pulmonary diseases and cystic fibrosis, among other conditions. Its B1 designation indicates it issued without post-issuance amendment.
OPEP devices represent a competitive and commercially significant segment of the respiratory therapeutics market, with established players including Trudell Medical International — makers of the Aerobika device — and Monaghan Medical Corp. A patent in this space that survives even partial Federal Circuit review carries meaningful enforcement weight. For competitors and new entrants, US9808588B1 represents a monitored risk asset; for D R Burton Healthcare, it is the foundation of an ongoing licensing and enforcement strategy that the remand will continue to test.
Should your team run an FTO against US9808588B1?
Any company developing, manufacturing, or distributing oscillating positive respiratory pressure devices should treat US9808588B1 as an active enforcement risk. The Federal Circuit’s partial affirmance means at least some claims remain viable. R&D teams designing OPEP mechanisms, valve systems, or pressure-regulation architectures should assess overlap with this patent’s claim scope before entering production or seeking regulatory clearance. The remand outcome may adjust that scope, but the risk is live today.
PatSnap Eureka’s FTO Search Agent can map the enforceable claim landscape of US9808588B1 against your product specifications, flag design-around opportunities, and monitor case developments as the remand progresses. With the Federal Circuit having already shaped the boundaries of the patent through its split ruling, a targeted Eureka FTO analysis will surface which claim elements survived and where your product sits relative to those boundaries.
Run a freedom-to-operate analysis on US9808588B1 to assess your product’s exposure
Run FTO in Eureka →Similar Federal Circuit appeals involving respiratory device and medical device patents
Browse Federal Circuit patent appeals in the respiratory device and OPEP technology space, including related infringement and claim construction disputes handled by this court.
What this case signals for the respiratory device IP landscape
A split Federal Circuit ruling on an OPEP device patent sends a nuanced signal to competitors and patent holders across the respiratory therapeutics sector.
Split rulings extend uncertainty — budget for remand litigation costs
When the Federal Circuit affirms in part and reverses in part, neither side can declare victory. R&D and legal teams in the respiratory device space should model continued litigation timelines and costs — the remand phase can take an additional one to three years before final resolution at the district court level.
US9808588B1 remains a live enforcement risk for OPEP device makers
The partial affirmance confirms that at least some claims of US9808588B1 survived Federal Circuit scrutiny. Any company developing or manufacturing oscillating positive respiratory pressure devices should conduct a current FTO analysis against this patent and monitor the remand proceedings closely before commercialising competing products.
D v Trudell — key questions answered
The Federal Circuit issued a split ruling in case 23-1779, affirming-in-part, reversing-in-part, and remanding the case. Neither party achieved a complete win. The appeal was also partially dismissed, indicating some issues were not addressed on the merits. The case was closed on 7 February 2025, but the remand means litigation continues at the lower tribunal level.
US9808588B1 covers oscillating positive respiratory pressure (OPEP) device technology — therapeutic devices that generate oscillating back-pressure to aid airway clearance. D R Burton Healthcare, LLC asserted this patent against Trudell Medical International and Monaghan Medical Corp., both established competitors in the respiratory device market. The case centred on an infringement action in this commercially significant segment.
It means the Federal Circuit upheld some lower-court findings but found reversible error on at least one material issue. US9808588B1 remains at least partially enforceable, but the scope of its valid and infringed claims will be shaped by the remand proceedings. The patent has not been invalidated or fully upheld — its effective scope is still being adjudicated.
The defendants were Trudell Medical International and Monaghan Medical Corp. Trudell Medical is a Canadian respiratory device company known for products such as the Aerobika OPEP device. Monaghan Medical Corp. is a US-based respiratory device company. Both are significant commercial players in the airway clearance and respiratory therapy sector targeted by D R Burton Healthcare’s patent assertion.
Following the Federal Circuit’s order, the specified reversed issues return to the lower tribunal for reconsideration consistent with the appellate court’s guidance. The lower court must address those issues anew, which typically extends the overall litigation timeline by one to several years. Parties and interested competitors should monitor the remand docket for further rulings on claim scope, validity, or damages as applicable.
PatSnap Eureka searches patents and litigation data to answer instantly.